- recruitingTherapeutic confirmatory (Phase III)
A Phase 3, 52-Week, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Adult Subjects With Prurigo Nodularis Who are Inadequately Controlled on Topical Therapies or Not Eligible for Topical Therapies
This study tests whether a new medicine called rocatinlimab helps adults with prurigo nodularis. This skin condition causes intensely itchy, firm lumps to form on the skin. The trial checks if the treatment can reduce severe itching and heal skin bumps when prescription creams have not provided enough relief.
Greece · Hungary · Romania - recruitingTherapeutic confirmatory (Phase III)
A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis
This study looks at a medicine called nemolizumab for adults with prurigo nodularis. Prurigo nodularis is a skin condition that causes hard, very itchy lumps. Doctors want to see if nemolizumab is safe and effective at calming severe itch and clearing skin nodules over a longer period.
Sweden · Germany · Spain - recruitingTherapeutic confirmatory (Phase III)
INCB 18424-319: A phase 3, double-blind, randomised, vehicle-controlled, efficacy and safety study of ruxolitinib cream in participants with Purigo Nodularis. Topical ruxolitinib evaluation in Prurigo Nodularis (TRuE-PN1)
This study is testing a new cream for Prurigo Nodularis, a skin condition causing very itchy bumps. It compares a cream with the active medicine to a plain cream, to see if the new medicine can help reduce itchiness and improve the skin condition over 12 weeks.
Spain · Italy · Belgium - recruitingTherapeutic confirmatory (Phase III)
INCB 18424-320: A phase 3, double-blind, randomised, vehicle-controlled, efficacy and safety study of ruxolitinib cream in participants with Prurigo Nodularis. Topical ruxolitinib evaluation in Prurigo Nodularis (TRuE-PN2)
This study is testing a new cream for people with very itchy skin lumps called Prurigo Nodularis. It wants to see if the cream, called ruxolitinib, can reduce itching compared to a cream without any medicine in it. The study aims to find out how well it works and if it's safe.
Austria · Poland · Spain - active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
This study is looking into a new medication called povorcitinib for people with prurigo nodularis, a skin condition causing very itchy bumps. It aims to see how well it reduces itching and skin problems, and if it's safe to use.
United States · Australia · Belgium - active not recruiting
Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study
This study looks at how a medicine called dupilumab works for people with prurigo nodularis in everyday life. Researchers want to see how well it helps manage the condition and how it's being used by patients in different countries.
United States · Canada · China - active not recruitingPHASE3
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis
This study is testing a new medicine, rocatinlimab, for adults with prurigo nodularis. It's designed to see if the medicine can reduce itching and improve skin compared to a dummy medicine, to help people with this itchy skin condition.
United States · Argentina · Australia - active not recruitingPHASE3
A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
This study looks at the long-term safety of a new medicine called Nemolizumab for people with Prurigo Nodularis. It's for those who have already tried Nemolizumab in a previous study for this skin condition.
United States · Austria · Belgium